OR WAIT 15 SECS
The value of the Colorectal Cancer (CRC) therapeutics market will increase from $8.3 billion in 2013 to $9.4 billion by 2020, according to a report from GBI Research.
The value of the Colorectal Cancer (CRC) therapeutics market will increase moderately, from $8.3 billion in 2013 to $9.4 billion by 2020, despite the upcomiong patent expirations of Avastin and Erbitux, according to a report from GBI Research. Avastin is however expected to retain its market-leading position in the global CRC space through to 2020, commented GBI senior analyst Saurabh Sharma. Stivarga is also expected to be one of the biggest drivers of growth in the market, "due primarily to its anticipated line extension as a maintenance treatment in the first-line metastatic setting for patients with resected liver metastases". While multiple new pipeline agents are expected to be launched in the CRC therapeutics market over the forecast period, Sharma added that none of these drugs will have a dramatic impact on the overall arena.